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T h ep a s td e c a d eh a sw i t n e s s e dat r u er e v o l u t i o ni no u r
understanding of how RNA can act as regulator of gene
functions. Central to these new advances is a growing ap-
preciation that small interfering RNAs (siRNAs) can in-
duce sequence-speciﬁc destruction of homologous mRNAs
in mammalian cells via a natural process referred as RNA in-
terference (RNAi). During a period of only ﬁve years, RNAi
has grown from a biological phenomenon to one of the most
widely used tools in research. In eﬀort to facilitate functional
genomics with RNAi, several libraries of siRNAs or short
hairpin RNAs have been constructed and screened in vitro
and in vivo. Although RNAi has many advantages over other
methods such as antisense and ribozyme technologies, the
speciﬁcity of silencing is not absolute and there is a danger
of “oﬀ-target eﬀects,” and activation of the innate immunity.
Notably, the success of siRNAs as therapeutic agents largely
depends on the development of a delivery vehicle that can
eﬃciently deliver them to speciﬁc tissues or cells. A deeper
understanding of the mechanisms of RNAi should allow bet-
ter design of siRNA agents. The purpose of this issue is to
review this exciting ﬁeld and to provide the reader with cur-
rent design rules, delivery strategies, and methods to mini-
mize unintended siRNA eﬀects.
ItshouldbenotedthattheemergenceofRNAihashelped
to clarify another enigma of noncoding temporal RNAs or
microRNAs (miRNAs). These tiny RNA regulators are being
implicated in diverse biological pathways, ranging from de-
velopment to neuronal diﬀerentiation and insulin produc-
tion. In addition to their roles in cell biology, recent studies
have implicated miRNAs in tumorogenesis and metastasis.
Indeed, gene proﬁling analysis found a number of miRNAs
that were upregulated in various cancers, which suggests a
potential diagnostic and prognostic value. Also, the identiﬁ-
cation of virus-encoded miRNAs indicate that some viruses
are able of exploiting RNA silencing as a convenient method
for gene regulation of host and viral genes. Although we
have learned much about the general mechanism underlying
miRNAbiogenesis,adetailedunderstandingofhowmiRNAs
and related small RNAs work remains to be elucidated. This
issue on RNAi also highlights the recent advances in under-
standing the biogenesis and expression of miRNAs in mam-
malian cells.
As our understanding of the functions of small RNAs
andthemechanismsbywhichRNAactivateinnateimmunity
continues to increase, we should become better equipped to
translate this naturally occurring process into our own ther-
apeutic beneﬁt.
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